Skip to main content

Table 3 Summary of prior therapy

From: Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

Characteristics No. of patients %
No. of chemotherapy regimens before gefitinib  
   1 2 18
   2 4 36
   3 4 36
   4 1 9
Best response to gefitinib   
   PR 8 73
   SD 3 27
PFS to gefitinib   
   Median 9.8  
   95% CI 6.6 - 16.7  
Interval from discontinuation of gefitinib to 2nd EGFR-TKI  
   Median 2.8  
   95% CI 1.9 - 6.9